The SSR4 is overexpressed in immune cells of the tumor microenvironment (TME) in colon adenocarcinoma and gastric cancer (9, 10) and may serve as a prognostic biomarker that can predict better overall survival (OS) and therapeutic efficiency in patients with colon adenocarcinoma. Here, SSR4 is linked to colon adenocarcinoma.